Gene-editing startup Editas files for IPO

Image: Feng Zhang with student

Broad Institute researcher Feng Zhang, one of the founders of Editas Medicine, works in his lab with graduate student Patrick Hsu. (Credit: Justin Knight / NSF)

Editas Medicine filed the paperwork for an initial public offering today, marking a first for the growing number of private ventures that aim to take advantage of a powerful gene-editing technology known as CRISPR-Cas9.

Among Editas’ private investors are Bng0, an investment company with funds from Microsoft co-founder Bill Gates; Google Ventures, the venture capital fund associated with Alphabet; and Khosla Ventures, the fund fronted by startup whiz Vinod Khosla. The company is collaborating with Seattle-based Juno Therapeutics on cancer treatments that take advantage of immunotherapy.

Editas was founded by several of the pioneers in the use of CRISPR-Cas9, a method that lets researchers snip and edit a wide variety of genomes to correct glitches or insert new code.

Get the full story from GeekWire.

About Alan Boyle

Aerospace and science editor for GeekWire, creator of Cosmic Log, author of "The Case for Pluto: How a Little Planet Made a Big Difference," president of the Council for the Advancement of Science Writing. Check out "About Alan Boyle" for more fun facts.
This entry was posted in GeekWire and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.